MGMT and central nervous system cancer: The methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is not only helpful in determining the grade and prognosis of glioma but also an important predictive biomarker of the benefit from alkylating agent therapy in glioblastoma (6, 7).